Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Modulating CYP450 Isozymes to Prevent DB[a, l]P-Induced Mammary Cancer

Modulating CYP450 Isozymes to Prevent DB[a, l]P-Induced Mammary Cancer

Ahmad Khan, Mohammad Kalim
Akhtar, Salman
Azeem, Mohd Umar

Paperback

General Computers

ISBN10: 6208417155
ISBN13: 9786208417154
Publisher: LAP Lambert Academic Publishing
Published: Dec 18 2024
Pages: 112
Weight: 0.39
Height: 0.27 Width: 6.00 Depth: 9.00
Language: English
Carcinogens transform into electrophilic metabolites, bind to DNA, and cause cancer via metabolic activation, detoxification, angiogenesis, and metastasis. CYP isozymes are therapeutic targets in DBP-induced mammary cancer. LBVS, molecular docking, MD simulations, and in vitro studies have focused on CYP1A1, 1A2, and 1B1. LBVS identified hits, refined using Lipinski's RO5 and ADMET filters, and docked them using AutoDock4. CHEMBL1, CHEMBL2, and CHEMBL3 showed superior binding affinities to ANF. The stability was confirmed via MD simulations. ADMET filtering yielded nontoxic hits, with ANA8430692 and ANA7923580 exhibiting optimal stability. Molecular dynamics and enzyme inhibition assays validated their potential as CYP inhibitors. Designed analogs ANA6917483, ANA8430692, and ANA6451816 displayed strong binding and interaction patterns, suggesting anticancer potential. This study enhances our understanding of the DBP-induced prevention of mammary cancer.

Also from

Ahmad Khan, Mohammad Kalim

View All

Also in

General Computers

View All